# Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

> **NCT01270438** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Adenocarcinoma of the Colon
- Adenocarcinoma of the Rectum
- Recurrent Colon Cancer
- Recurrent Rectal Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **BIOLOGICAL:** bevacizumab
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin calcium
- **DRUG:** fluorouracil

## Key facts

- **NCT ID:** NCT01270438
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2011-08
- **Final completion:** 2013-08
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01270438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01270438, "Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT01270438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*